Editorial policy

Scope

This policy governs every article published on 30-g.com. It is written for our readers, not for our writers — if anything we publish doesn’t match what’s described here, please tell us.

What we write about

We cover the practical experience of self-injecting insulins prescribed in the EU and UK: needle and pen-needle selection, injection technique, site rotation, storage, travel, sharps disposal, and the patient-side mechanics of devices like the SoloStar, FlexTouch, FlexPen and KwikPen.

We do not write articles that:

• Recommend a specific dose, schedule or treatment for any prescription medication
• Make claims about the comparative effectiveness of one prescription drug over another
• Present any of our writers as qualified clinicians, doctors, nurses or pharmacists
• Promote off-label use of any medication
• Discuss compounded or unlicensed insulin products

If a topic falls outside that scope, we point readers to the appropriate authority — typically the EMA, FDA, NICE, NHS or their prescriber.

Sourcing standard

Every clinical, pharmacological, regulatory or numerical claim must trace to one of:

1. The drug’s FDA label (accessdata.fda.gov)
2. The drug’s EMA Summary of Product Characteristics (ema.europa.eu)
3. NICE clinical guidance or technology appraisals (nice.org.uk)
4. NHS patient information pages (nhs.uk, medicines.org.uk)
5. Manufacturer Instructions for Use (the official PDF distributed with the device)
6. Peer-reviewed papers indexed on PubMed, cited by PMID and DOI

Secondary sources (American Diabetes Association, International Diabetes Federation, Diabetes UK, British Menopause Society, Endocrine Society) are acceptable for clinical-consensus statements but never for primary numerical or pharmacological facts.

We do not source claims from Healthline, WebMD, Drugs.com, Patient.info, Reddit, manufacturer marketing sites, or other content sites.

Use of generative AI

We disclose this clearly: our editorial workflow uses generative AI to draft articles, which are then edited, fact-checked against the sources above, and published under a real human byline.

We use AI in the same way many publishers in 2026 do — to accelerate the first draft, restructure outlines, and translate technical primary-source language into plain prose. We don’t use it to invent facts, fabricate citations, generate fake first-person experiences, or replace human judgment about what’s safe to publish.

Every article is read end-to-end by a named member of our team before it goes live. They are responsible for the article. Their byline links to their LinkedIn so you can see who they actually are.

What we will not do

• We will not invent test data, customer surveys, or “first-person experience” we don’t have. Where an article would benefit from original measurements or a controlled experiment we haven’t run, we leave that section out rather than fabricate it.
• We will not add a fake medical reviewer line. None of our writers are licensed clinicians, so no article on 30-g.com carries a “Reviewed by Dr. [Name], MD” stamp. We disclose this on every article and direct readers to verify clinical decisions with their actual prescriber.
• We will not accept payment from drug or device manufacturers in exchange for editorial coverage. Our commercial support comes from our sister company InjectKit.com, which sells the supplies we write about. That relationship is disclosed at the top and bottom of every article.

Corrections

If we publish something wrong, here’s how it gets fixed:

1. Email [email protected] with the subject “Correction: [article URL]” and the specific claim that’s wrong, ideally with a primary source we can check.
2. We aim to respond within 3 business days.
3. If a correction is warranted, we: - Update the article - Bump the “Last reviewed” date - Add a line to the changelog at the bottom of that article describing what changed - Log the same correction in the changelog of this policy page if it concerns sourcing standards
4. Significant corrections — anything that materially changes the safety or pharmacological information in the article — are also flagged in a corrections list maintained on this site.

Conflicts of interest

We are owned by meeco Servicios Globales S.L., which also owns InjectKit.com, an EU medical-supplies retailer. Articles on 30-g.com link to relevant InjectKit product pages where editorially appropriate. We do not have undisclosed commercial relationships with any other party.

If a writer or contributor on 30-g.com has a personal or financial conflict of interest with a topic — for example, an undeclared pharmaceutical industry relationship — they recuse themselves from that article and we disclose the recusal.

Changelog

• 2026-04-25 — Editorial policy first published.